BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28559017)

  • 1. Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: An analysis of 614 patients from a single center.
    Wu LR; Liu YT; Jiang N; Fan YX; Wen J; Huang SF; Guo WJ; Bian XH; Wang FJ; Li F; Song D; Wu JF; Jiang XS; Liu JY; He X
    Oral Oncol; 2017 Jun; 69():26-32. PubMed ID: 28559017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.
    Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T
    Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of long-term survival outcomes and failure patterns of patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: a retrospective analysis.
    Zhao W; Lei H; Zhu X; Li L; Qu S; Liang X
    Oncotarget; 2016 Dec; 7(52):86914-86925. PubMed ID: 27894100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study comparing the outcomes and toxicities of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma.
    Qiu WZ; Peng XS; Xia HQ; Huang PY; Guo X; Cao KJ
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1563-1572. PubMed ID: 28342002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognoses and long-term outcomes of nasopharyngeal carcinoma in Han and Uyghur patients treated with intensity-modulated radiotherapy in the Xinjiang Autonomous Region of China.
    Wang R; Tan Y; Wang X; Ma L; Wang D; Hu Y; Qin Y; Liu K; Chang C; Yu J
    PLoS One; 2014; 9(11):e111145. PubMed ID: 25375129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy.
    He YX; Wang Y; Cao PF; Shen L; Zhao YJ; Zhang ZJ; Chen DM; Yang TB; Huang XQ; Qin Z; Dai YY; Shen LF
    Chin J Cancer; 2016 Nov; 35(1):96. PubMed ID: 27852284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update report of T4 classification nasopharyngeal carcinoma after intensity-modulated radiotherapy: an analysis of survival and treatment toxicities.
    Cao CN; Luo JW; Gao L; Yi JL; Huang XD; Wang K; Zhang SP; Qu Y; Li SY; Xiao JP; Zhang Z; Xu GZ
    Oral Oncol; 2015 Feb; 51(2):190-4. PubMed ID: 25434585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy.
    Mao YP; Tang LL; Chen L; Sun Y; Qi ZY; Zhou GQ; Liu LZ; Li L; Lin AH; Ma J
    Chin J Cancer; 2016 Dec; 35(1):103. PubMed ID: 28031050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience.
    Kam MK; Teo PM; Chau RM; Cheung KY; Choi PH; Kwan WH; Leung SF; Zee B; Chan AT
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1440-50. PubMed ID: 15590175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and toxicity of individualized intensity-modulated radiotherapy based on the tumor extension patterns of nasopharyngeal carcinoma.
    Lin L; Yao JJ; Zhou GQ; Guo R; Zhang F; Zhang Y; Xu L; Zhang LL; Lin AH; Ma J; Sun Y
    Oncotarget; 2016 Apr; 7(15):20680-90. PubMed ID: 26980744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome for nasopharyngeal carcinoma with predominantly WHO II histology treated with intensity-modulated radiation therapy in non-endemic region of China.
    Zhao LN; Zhou B; Shi M; Wang JH; Xiao F; Xu M; Luo SQ; Xue Y; Li JP; Tan LN
    Oral Oncol; 2012 Sep; 48(9):864-9. PubMed ID: 22445296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma.
    Peng G; Wang T; Yang KY; Zhang S; Zhang T; Li Q; Han J; Wu G
    Radiother Oncol; 2012 Sep; 104(3):286-93. PubMed ID: 22995588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and toxicities of intensity-modulated radiation therapy for patients with T4 nasopharyngeal carcinoma.
    Kong FF; Ying H; Du CR; Huang S; Zhou JJ; Hu CS
    PLoS One; 2014; 9(3):e91362. PubMed ID: 24608637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.
    Lu TX; Mai WY; Teh BS; Zhao C; Han F; Huang Y; Deng XW; Lu LX; Huang SM; Zeng ZF; Lin CG; Lu HH; Chiu JK; Carpenter LS; Grant WH; Woo SY; Cui NJ; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):682-7. PubMed ID: 14967420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience.
    Wolden SL; Chen WC; Pfister DG; Kraus DH; Berry SL; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):57-62. PubMed ID: 15936155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
    You R; Sun R; Hua YJ; Li CF; Li JB; Zou X; Yang Q; Liu YP; Zhang YN; Yu T; Cao JY; Zhang MX; Jiang R; Mo HY; Guo L; Cao KJ; Lin AH; Qian CN; Sun Y; Ma J; Chen MY
    Int J Cancer; 2017 Sep; 141(6):1265-1276. PubMed ID: 28577306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intensity modulated radiation therapy for 90 untreated nasopharyngeal carcinoma].
    Wei R; Jiang W; Su J; He L; Yang Z; Jiang W
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Feb; 37(2):173-8. PubMed ID: 22561435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensity-modulated radiotherapy.
    Takiar V; Ma D; Garden AS; Li J; Rosenthal DI; Beadle BM; Frank SJ; Fuller CD; Gunn GB; Morrison WH; Hutcheson K; El-Naggar AK; Gold KA; Kupferman ME; Phan J
    Head Neck; 2016 Apr; 38 Suppl 1():E925-33. PubMed ID: 25994561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensity-modulated radiotherapy (IMRT)/Tomotherapy following neoadjuvant chemotherapy in stage IIB-IVA/B undifferentiated nasopharyngeal carcinomas (UCNT): a mono-institutional experience.
    Franchin G; Vaccher E; Talamini R; Politi D; Gobitti C; Minatel E; Lleshi A; Sartor G; Mascarin M; Rumeileh IA; Trovò MG; Barzan L
    Oral Oncol; 2011 Sep; 47(9):905-9. PubMed ID: 21783403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series.
    Lin S; Pan J; Han L; Zhang X; Liao X; Lu JJ
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1071-8. PubMed ID: 19362784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.